PMC:7060195 / 2885-3870 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"52","span":{"begin":799,"end":805},"obj":"Species"},{"id":"53","span":{"begin":832,"end":840},"obj":"Disease"}],"attributes":[{"id":"A52","pred":"tao:has_database_id","subj":"52","obj":"Tax:9606"},{"id":"A53","pred":"tao:has_database_id","subj":"53","obj":"MESH:D064420"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Vaccine strategy Advantages Disadvantages References\nInactivated virus vaccines Easy to prepare; safety; high-titer neutralizing antibodies Potential inappropriate for highly immunosuppressed individuals 25\nAttenuated virus vaccines Rapid development; induce high immune responses Phenotypic or genotypic reversion possible; can still cause some disease 25\nSubunit vaccines High safety; consistent production; can induce cellular and humoral immune responses; high-titer neutralizing antibodies High cost; lower immunogenicity; require repeated doses and adjuvants 12,14\nViral vector vaccines Safety; induces high cellular and humoral immune responses Possibly present pre-existing immunity 12\nDNA vaccines Easier to design; high safety; high-titer neutralizing antibodies Lower immune responses in humans; repeated doses may cause toxicity 23\nmRNA vaccines Easier to design; high degree of adaptability; induce strong immune responses Highly unstable under physiological conditions 23"}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T5","span":{"begin":694,"end":697},"obj":"Body_part"},{"id":"T6","span":{"begin":844,"end":848},"obj":"Body_part"}],"attributes":[{"id":"A5","pred":"fma_id","subj":"T5","obj":"http://purl.org/sig/ont/fma/fma74412"},{"id":"A6","pred":"fma_id","subj":"T6","obj":"http://purl.org/sig/ont/fma/fma67122"}],"text":"Vaccine strategy Advantages Disadvantages References\nInactivated virus vaccines Easy to prepare; safety; high-titer neutralizing antibodies Potential inappropriate for highly immunosuppressed individuals 25\nAttenuated virus vaccines Rapid development; induce high immune responses Phenotypic or genotypic reversion possible; can still cause some disease 25\nSubunit vaccines High safety; consistent production; can induce cellular and humoral immune responses; high-titer neutralizing antibodies High cost; lower immunogenicity; require repeated doses and adjuvants 12,14\nViral vector vaccines Safety; induces high cellular and humoral immune responses Possibly present pre-existing immunity 12\nDNA vaccines Easier to design; high safety; high-titer neutralizing antibodies Lower immune responses in humans; repeated doses may cause toxicity 23\nmRNA vaccines Easier to design; high degree of adaptability; induce strong immune responses Highly unstable under physiological conditions 23"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T21","span":{"begin":65,"end":70},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T22","span":{"begin":218,"end":223},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T23","span":{"begin":799,"end":805},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9606"}],"text":"Vaccine strategy Advantages Disadvantages References\nInactivated virus vaccines Easy to prepare; safety; high-titer neutralizing antibodies Potential inappropriate for highly immunosuppressed individuals 25\nAttenuated virus vaccines Rapid development; induce high immune responses Phenotypic or genotypic reversion possible; can still cause some disease 25\nSubunit vaccines High safety; consistent production; can induce cellular and humoral immune responses; high-titer neutralizing antibodies High cost; lower immunogenicity; require repeated doses and adjuvants 12,14\nViral vector vaccines Safety; induces high cellular and humoral immune responses Possibly present pre-existing immunity 12\nDNA vaccines Easier to design; high safety; high-titer neutralizing antibodies Lower immune responses in humans; repeated doses may cause toxicity 23\nmRNA vaccines Easier to design; high degree of adaptability; induce strong immune responses Highly unstable under physiological conditions 23"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T7","span":{"begin":555,"end":564},"obj":"Chemical"},{"id":"T8","span":{"begin":694,"end":697},"obj":"Chemical"}],"attributes":[{"id":"A7","pred":"chebi_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/CHEBI_60809"},{"id":"A8","pred":"chebi_id","subj":"T8","obj":"http://purl.obolibrary.org/obo/CHEBI_16991"}],"text":"Vaccine strategy Advantages Disadvantages References\nInactivated virus vaccines Easy to prepare; safety; high-titer neutralizing antibodies Potential inappropriate for highly immunosuppressed individuals 25\nAttenuated virus vaccines Rapid development; induce high immune responses Phenotypic or genotypic reversion possible; can still cause some disease 25\nSubunit vaccines High safety; consistent production; can induce cellular and humoral immune responses; high-titer neutralizing antibodies High cost; lower immunogenicity; require repeated doses and adjuvants 12,14\nViral vector vaccines Safety; induces high cellular and humoral immune responses Possibly present pre-existing immunity 12\nDNA vaccines Easier to design; high safety; high-titer neutralizing antibodies Lower immune responses in humans; repeated doses may cause toxicity 23\nmRNA vaccines Easier to design; high degree of adaptability; induce strong immune responses Highly unstable under physiological conditions 23"}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T2","span":{"begin":264,"end":280},"obj":"http://purl.obolibrary.org/obo/GO_0006955"},{"id":"T3","span":{"begin":434,"end":458},"obj":"http://purl.obolibrary.org/obo/GO_0006959"},{"id":"T4","span":{"begin":627,"end":651},"obj":"http://purl.obolibrary.org/obo/GO_0006959"},{"id":"T5","span":{"begin":779,"end":795},"obj":"http://purl.obolibrary.org/obo/GO_0006955"},{"id":"T6","span":{"begin":919,"end":935},"obj":"http://purl.obolibrary.org/obo/GO_0006955"}],"text":"Vaccine strategy Advantages Disadvantages References\nInactivated virus vaccines Easy to prepare; safety; high-titer neutralizing antibodies Potential inappropriate for highly immunosuppressed individuals 25\nAttenuated virus vaccines Rapid development; induce high immune responses Phenotypic or genotypic reversion possible; can still cause some disease 25\nSubunit vaccines High safety; consistent production; can induce cellular and humoral immune responses; high-titer neutralizing antibodies High cost; lower immunogenicity; require repeated doses and adjuvants 12,14\nViral vector vaccines Safety; induces high cellular and humoral immune responses Possibly present pre-existing immunity 12\nDNA vaccines Easier to design; high safety; high-titer neutralizing antibodies Lower immune responses in humans; repeated doses may cause toxicity 23\nmRNA vaccines Easier to design; high degree of adaptability; induce strong immune responses Highly unstable under physiological conditions 23"}

{"project":"LitCovid-sentences","denotations":[{"id":"T22","span":{"begin":0,"end":52},"obj":"Sentence"},{"id":"T23","span":{"begin":53,"end":206},"obj":"Sentence"},{"id":"T24","span":{"begin":207,"end":356},"obj":"Sentence"},{"id":"T25","span":{"begin":357,"end":570},"obj":"Sentence"},{"id":"T26","span":{"begin":571,"end":693},"obj":"Sentence"},{"id":"T27","span":{"begin":694,"end":843},"obj":"Sentence"},{"id":"T28","span":{"begin":844,"end":985},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Vaccine strategy Advantages Disadvantages References\nInactivated virus vaccines Easy to prepare; safety; high-titer neutralizing antibodies Potential inappropriate for highly immunosuppressed individuals 25\nAttenuated virus vaccines Rapid development; induce high immune responses Phenotypic or genotypic reversion possible; can still cause some disease 25\nSubunit vaccines High safety; consistent production; can induce cellular and humoral immune responses; high-titer neutralizing antibodies High cost; lower immunogenicity; require repeated doses and adjuvants 12,14\nViral vector vaccines Safety; induces high cellular and humoral immune responses Possibly present pre-existing immunity 12\nDNA vaccines Easier to design; high safety; high-titer neutralizing antibodies Lower immune responses in humans; repeated doses may cause toxicity 23\nmRNA vaccines Easier to design; high degree of adaptability; induce strong immune responses Highly unstable under physiological conditions 23"}